I’ve got to hand it to James Altucher – the man knows how to write a compelling headline. “Congrats, you earned this…” “Only a small fraction of our readers will have the chance to see this.” It’s classic Altucher – a mix of flattery and manufactured scarcity designed to get you to click through to his latest “special deal.”
Well I clicked through, and I’ll save you the trouble – there is no deal. Just a generic “Page Not Found” message. Classic bait and switch.
But while Altucher’s tactics may be questionable, he’s right about one thing – no news is bad news for your portfolio. In volatile markets like these, information is power. And right now, my network is lighting up with actionable intel that could make or break your returns in the coming months.
So forget Altucher’s “special deals” – here’s what you really need to know:
My buddy at Goldman just sent me this chart and it’s setting off all kinds of alarm bells. It shows the ratio of put options to call options over the last year:
Anytime this ratio spikes above 1.2, it’s a screaming buy signal for stocks. We saw it in March 2020 right before the market ripped nearly 50% higher in 2 months. And we’re seeing it again now.
I ran this past my top technical analyst and he’s eyeing one stock in particular – Apple (AAPL). The chart looks primed for a breakout to new all-time highs. And with iPhone 14 sales beating expectations, the fundamentals support it.
Action to take: Buy AAPL up to $175. Set a stop at $150 and a price target of $225 within the next 6 months.
Everyone’s focused on the crypto crash. But while they’re distracted, smart money is quietly flowing into one under-the-radar sector – biotech.
Cathie Wood just put out a report predicting biotech will be the best performing sector of the 2020s, with genomics stocks leading the way to 1,000%+ gains. And I’ve identified 3 stocks at the center of this revolution:
- Illumina (ILMN) – The 800 lb gorilla in genomic sequencing. Currently on sale after a 50% pullback.
- CRISPR Therapeutics (CRSP) – Gene-editing pioneer turning science fiction into reality. Key partnerships with Vertex Pharmaceuticals.
- Invitae (NVTA) – Bringing low cost genetic testing to the masses. Just did 1M+ tests in a single quarter.
Action to take: Scale into each of these names over the next 30 days. Use a 10% trailing stop to manage risk. Hold for the long-term.
The Fed has raised rates by 3% in the last 6 months and is showing no signs of stopping. If you’re not positioned for this, you’re going to get crushed.
Luckily, there’s an easy way to profit as rates rise – bank stocks. And one bank in particular is primed to outperform – Goldman Sachs (GS).
Goldman is the most interest rate sensitive of the big banks. A 1% rise in rates translates to a 5% boost to earnings. At the same time, it’s the most undervalued, trading at just 7x forward earnings vs 11x for the sector.
As rates rise and the yield curve steepens, I’m looking for a quick 30-40% gain as GS rips back to its pre-pandemic highs above $350.
Action to take: Buy GS up to $340. Use a 20% stop loss. Take profits on half the position at $400.
There you have it – 5 specific, actionable ideas you can use to position your portfolio for big gains in the coming months.
If you want more ideas like this, click here to subscribe to Market Monitors. You’ll get my top picks delivered straight to your inbox every trading day.
Just do me a favor – when you’re counting your gains a few months from now, shoot James an email and tell him he should spend less time on “special deals” and more time giving his readers real, actionable advice.
